Comments
Glenmark Specialty SA of Glenmark Pharmaceutical has received final approval from the United States Food & Drug Administration (USFDA) for Esomeprazole Magnesium delayed-release capsules USP, 20 mg (OTC).
The capsule will be distributed in the US by Glenmark Therapeutics Inc., USA. It is bioequivalent to Nexium 2 24 HR delayed-release capsules, 20 mg (OTC), of Haleon U.S. Holdings LLC.
Shares of Glenmark Pharmaceuticals traded at ₹1,188.90 on the NSE, down by 0.16 per cent as of 9.54 am.
- Also read: Glenmark, BeiGene team up to introduce advanced cancer therapies in India; stock trade flat
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.